MEDVi Review 2026

What They Offer

MEDVi is a telehealth platform offering compounded semaglutide and tirzepatide through its partner network, OpenLoop Health (a network of U.S.-licensed physicians). Unlike most competitors, MEDVi offers both an injectable and a dissolvable-tablet format for each medication — a genuinely differentiated option for patients who prefer oral administration or struggle with injections. The platform is cash-pay and ships medication direct to home from licensed pharmacies. Brand-name Wegovy and Zepbound are also offered, through a separate $99/month membership plus medication cost that MEDVi does not publish.

Pricing & Plans

"First month" and "ongoing" figures come from MEDVi's own marketing and terms pages, cross-checked against repeated independent verification. We flag this because MEDVi's live order page (glp1.medvi.org) has displayed a template rendering bug for months where these prices show as unrendered code instead of numbers, so a clean first-party read of the checkout itself has not been possible recently. Separately, MEDVi's site navigation currently also lists a standalone tirzepatide option (around $349/mo injection, $279/mo tablets) and a brand Ozempic option (around $1,999/mo) that are new since this page was last priced — we have not listed them above because we could not confirm their exact terms with confidence.

What's Included

• Physician review and clinical evaluation by OpenLoop Health providers
• Personalized weight loss plan and metabolic report
• One-on-one coaching with care team
• GLP-1 medication prescribed and shipped directly to home
• Free shipping on all orders
• Unlimited 24/7 messaging with care team
• Dosing guidance and side effect management
• No membership or subscription fees on the compounded path (brand-name Wegovy/Zepbound carry a separate $99/mo membership)
• A disputed refund clause — see "Is MEDVi Legitimate?" below before counting on it

Eligibility

Clinical Results & Effectiveness

MEDVi has not published independent, peer-reviewed outcome data for its own compounded semaglutide or tirzepatide. The "1–2 lbs per week" weight-loss figure that appears in MEDVi's own marketing carries a footnote defining it as "based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment" — 2.4 mg/week is the maintenance dose studied in the STEP trials of Novo Nordisk's FDA-approved semaglutide (Wegovy), not a measurement of MEDVi's own compounded patients. Reading trial results for one product as evidence for a different, compounded product is exactly the inference the National Advertising Division ruled unsubstantiated against a competitor (Willow) in December 2025, and it is why we removed the "85% of patients lose at least 5% of body weight" and "15–20% average weight loss" figures that previously appeared on this page — neither could be traced to a study of MEDVi's own product.

Compounded semaglutide and tirzepatide share an active ingredient with FDA-approved medications but are not themselves FDA-approved as finished products, and the FDA's February 2026 letter to MEDVi (below) specifically objected to language implying otherwise.

Is MEDVi Legitimate?

MEDVi is a real, operating telehealth company working with licensed U.S. providers through the OpenLoop Health network. It is not a shell operation and patients do receive medication. But there is regulatory and internal-consistency history worth knowing before you sign up.

FDA warning letter, February 20, 2026. The FDA's Center for Drug Evaluation and Research reviewed MEDVi's website (medvi.io) and found two issues. First, the compounded semaglutide and tirzepatide products pictured on MEDVi's site carried a "MEDVi" label, which the agency said falsely implied MEDVi itself compounded those drugs when it does not — making the products misbranded under FDCA sections 502(a) and 502(bb). Second, FDA objected to claims that the products have the "Same active ingredient as Wegovy® and Ozempic®" and "Same active ingredient as Mounjaro® and Zepbound®," saying this language implied FDA approval or evaluation the compounded products have not received. MEDVi was given 15 working days to describe corrective steps. This is an advertising and labeling enforcement action, not a finding of contamination, a recall, or evidence of patient harm — but it is the second time a provider covered on this site has received a similar letter for implying equivalence to an FDA-approved drug (see our Remedy Meds review). Read the letter yourself at FDA.gov.

A self-contradictory refund policy. MEDVi's general Terms and Conditions include a clause promising a refund (minus a 25% consult fee) if a customer can "demonstrate" no weight loss after 5 months. But MEDVi's separate, dedicated Cancellation and Refund Policy page states plainly: "There is no guarantee of results or effectiveness due to your participation in the Subscription Services," and limits refunds to two cases — cancelling within 72 hours before any service is delivered, or being medically disqualified by MEDVi's own provider. That page does not mention the 5-month clause at all. We read both documents directly; they do not agree with each other, and a customer relying on the "weight loss refund" described in MEDVi's marketing should get MEDVi to confirm the terms in writing rather than assume the version on this or any review page is the one that will apply to them.

Inconsistent patient counts. MEDVi's own site currently displays different total-patient figures in different places — "Join 500,000+ MEDVi patients" on one banner and "10,000+ Patients Agree" elsewhere on the same page — and earlier press coverage cited "100,000+ patients." We could not determine which figure, if any, is current, so we are not repeating a specific number.

Customer Experience

MEDVi has a large volume of reviews on Trustpilot — public review-page pagination suggests somewhere in the range of 10,000–14,000 reviews — with a rating that public listings place in the 4-star range. Trustpilot blocked automated verification during this review, so we are not repeating a precise decimal star rating or exact review count; confirm the current figure directly at Trustpilot before citing it elsewhere. Common praise in visible reviews focuses on quick approval and responsive care-team access. Complaints include billing errors such as double charges, medication switches without clear notice, and missed coaching sessions attributed to connection issues.

Frequently Asked Questions

Our Verdict

MEDVi's injectable-or-tablet choice for compounded semaglutide and tirzepatide is a genuine, useful differentiator, and its intake and approval process is fast. But this review's checks found more here than the original version disclosed: an FDA warning letter for misbranding (MEDVi's own site had implied it compounded drugs it does not, and used "same active ingredient" language the agency flagged), a refund policy that directly contradicts itself across MEDVi's own legal pages, weight-loss figures that trace to trial data for a different, FDA-approved product rather than MEDVi's own outcomes, and patient-count claims that vary depending which part of MEDVi's own site you read. None of that makes MEDVi a scam — it is a real, operating company, and the medication format flexibility is real. But the marketing overstates the case in ways that matter for a health decision, and the score reflects that.

Choose it if you specifically want a dissolvable-tablet alternative to injections and are comfortable with compounded medication. Look elsewhere if you are choosing MEDVi because of the advertised weight-loss refund — get the terms in writing first — or if an FDA warning letter for misbranding is disqualifying for you.

We may earn a commission if you sign up through our links. It never changes our rankings.